CORRELATION AMONG LIVER FUNCTION, INSULIN RESISTANCE, LIPID PROFILE, AND GLYCEMIC MARKERS IN TYPE 2 DIABETES MELLITUS PATIENTS
Main Article Content
Keywords
Type 2 Diabetes Mellitus, Insulin Resistance, Lipid Profile, Liver Function, Glycemic Markers.
Abstract
Background: Type 2 Diabetes Mellitus (T2DM) is associated with impaired glucose metabolism, insulin resistance, dyslipidemia, and hepatic dysfunction. Understanding the interrelationship between these metabolic parameters can improve clinical management and risk assessment.
Objective: To evaluate the correlation among glycemic markers, insulin resistance, lipid profile, and liver function in patients with T2DM.
Methods: A cross-sectional case-control study was conducted on 200 T2DM patients and 200 age- and gender-matched healthy controls at Krishna Mohan Medical College & Hospital, Mathura, from March 2024 to February 2025. Fasting blood glucose, HbA1c, HOMA-IR, lipid profile, and liver enzymes (ALT, AST, ALP) were measured. Data analysis was performed using SPSS v25.0, with independent sample t-tests and Pearson correlation; p < 0.05 was considered statistically significant.
Results: T2DM patients exhibited significantly elevated fasting glucose (156.8 ± 42.5 mg/dL), HbA1c (8.4±1.5%), HOMA-IR (4.8±1.9), total cholesterol (211.3±38.4 mg/dL), triglycerides (189.7±56.1 mg/dL), LDL-C (126.5±32.9 mg/dL), and liver enzymes (ALT 49.8±15.6 U/L, AST 45.2±14.2 U/L, ALP 122.6±31.8 U/L) compared to controls (all p < 0.05). HDL-C was significantly lower (38.9±8.2 mg/dL vs. 48.6±7.3 mg/dL, p < 0.001). HbA1c showed strong positive correlations with fasting glucose (r = 0.812) and HOMA-IR (r = 0.758), moderate positive correlations with total cholesterol, triglycerides, LDL-C, and weak positive correlations with liver enzymes. HDL-C correlated negatively with HbA1c.
Conclusion: T2DM patients demonstrate poor glycemic control, pronounced insulin resistance, dyslipidemia, and mild hepatic dysfunction. The observed correlations emphasize the interconnected nature of glucose metabolism, lipid abnormalities, and liver function, underscoring the importance of comprehensive metabolic monitoring in T2DM management.
References
2. J. Larry Jameson. HARRISON’S Endocrinology. 2nd ed. Chicago: Mc Graw Hill Medical; 2010.
3. Centers for Disease Control and prevention. National Diabetes Statistics Report 2020. Estimates of diabetes and its burden in the United States. United States: 2020 [cited 2023Sep22]. Available from: https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics- report.pdf
4. Jameson J. Larry, Fauci S. Anthony, Kasper L. Dennis, Hauser L. Stephen, Longo L. Dan, Loscalzo Joseph. Harrison’s Principles of Internal Medicine. 20th ed. Newyork and Chicago: McGraw-Hill Education; 2018.
5. Satyanarayana U, Chakrapani U. Biochemistry. 4th ed. New Delhi: Elsevier; 2013.
6. Hiroaki Ueno, Yukie Saitoh, Masanari Mizuta, Tomomi Shiiya, Kenji Noma, Shinichi Mashiba, et al. Fenofibrate ameliorates insulin resistance, hypertension and novel oxidative stress markers in patients with metabolic syndrome. Obes Res Clin Pract 2011;267–307.
7. Lee M, Sorn SR, Lee Y, Kang I. Salt induces adipogenesis/lipogenesis and inflammatory adipocytokines secretion in adipocytes. Int J Mol Sci 2019;20(1).
8. Molugu SV, et al. Lipid parameters and their association with liver function test variables in patients with type 2 diabetes mellitus. Cureus. 2025;17(9): e92671.
9. Zhang P, Yan J, Pan B, Liu J, Fu S, Cheng J, Li Q. Prevalence of dyslipidemia, treatment rate and its control among patients with type 2 diabetes mellitus in Northwest China: a cross sectional study. Lipids Health Dis. 2022; 21:123.
10. Ali SH, Naji HH, Al Hayani AJ, et al. The correlation study between lipid profile parameters and HbA1c in type 2 diabetic patients compared with healthy persons in Babylon Province. Clin Med Health Res J. 2024;4(2):893 899.
